You are here: Industry Insights > mRNA

News List

Scientists decode how coronavirus molecules camouflage in host cell expresspharma
July 27, 2020
According to the researchers, this development may pave the way for the design of new drugs against the novel coronavirus SARS-CoV-2, and other emerging coronavirus infections.
GSK Buys 10% Stake in German Vaccine Developer CureVac contractpharma
July 22, 2020
Companies will collaborate on the research and development mRNA vaccine candidates.
GSK to obtain 10% stake in vaccines maker CureVac for $163m pharmaceutical-technology
July 21, 2020
GlaxoSmithKline (GSK) has signed an agreement with German company CureVac to research, develop, manufacture and commercialise up to five mRNA-based vaccines and monoclonal antibodies (mAbs) against infectious diseases.
CureVac Receives Approval to Initiate Clinical Trial of SARS-CoV-2 Vaccine Candidate contractpharma
June 18, 2020
The Belgian Federal Agency for Medicines and Health Products (FAMHP) has approved the Phase 1 clinical trial for CureVac’s vaccine program to prevent SARS-CoV-2 infection. The trial will be conducted in Germany and Belgium.
Germany to invest €300m in CureVac’s mRNA platform technology pharmaceutical-technology
June 17, 2020
The German Federal Government is set to invest €300m in CureVac, a biotechnology company focused on using messenger RNA (mRNA) technology to develop drugs and vaccines.
German Government, dievini Invests €300M in CureVac contractpharma
June 16, 2020
To expand business activities and further develop CureVac’s pipeline and mRNA platform technology.
CordenPharma & Moderna Extend Manufacturing Agreement contractpharma
June 01, 2020
For the supply of lipid excipients to be used in Moderna's coronavirus vaccine.
mRNA-based vaccine technology innovate approach to treating COVID-19 expresspharma
May 29, 2020
Over 150 COVID-19 vaccines are currently under development by biopharma companies and research organisations around the world.
Arcturus Therapeutics, Catalent announce partnership to manufacture mRNA-based Covid-19 pharmaceutical-business-review
May 08, 2020
Arcturus Therapeutics Holdings, a leading clinical-stage messenger RNA (mRNA) medicines and vaccines company, and Catalent announced a partnership to support the expected manufacture of Arcturus’ COVID-19 mRNA vaccine candidate (LUNAR-COV19) .
First Patient Dosed With Pfizer’s Potential COVID-19 Vaccine in US europeanpharmaceuticalreview
May 07, 2020
Pfizer and BioNTech have initiated Phase I/II trials in the US to determine the safety and optimal dose of four mRNA COVID-19 vaccine candidates.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page